Status:
COMPLETED
Effect of Affective Content on Drug Induced Amnesia of Episodic Memory
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Memory Losses
Amnesia-Memory Loss
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this research is to understand how some of the drugs commonly used in anesthesia impair memory. We are particularly interested in whether the emotion associated with a memory influences...
Detailed Description
The protocol "Effect of Affective Content on Drug Induced Amnesia of Episodic Memory" investigates the relationship between the ability of affective ('emotional') content to modulate the formation of ...
Eligibility Criteria
Inclusion
- Healthy normal volunteers, age 18 to 50 years \*,who show no evidence of neurologic deficit on questionnaire and physical examination.
- Females must be non-pregnant as demonstrated using a serum pregnancy test.
- Right hand dominant.
- High school education or above.
- English as native language or equivalent degree of fluency. \*Age group selected based on pharmacokinetic models for drug infusion, and norms for standardized memory tests.
Exclusion
- Any evidence of neurologic deficit including seizures, severe head trauma resulting in unconsciousness, or any previously abnormal study of CNS - (e.g. MRI, EEG, etc.)
- Any deficit in auditory or visual ability.
- Any history of hypertension (resting BP \>150 systolic, \>100 diastolic) or taking anti- hypertensive medication or cardiovascular disease.
- Significant pulmonary, renal, gastrointestinal, or endocrine metabolic disease which in the opinion of the investigator would complicate the goals of this study.
- Allergy to propofol or eggs.
- History of acute intermittent porphyria in subject or subject's blood relatives.
- History of substance abuse
- Currently taking centrally acting medications (e,g, benzodiazepines or anti depressants)
- Subjects whose body weight relative to their height exceeds accepted criteria for defining obesity in the general population (Body Mass Index \> 30). Excess weight can affect the pharmacodynamics of the drug in the body.
- Anyone who, in the opinion of the investigators, would be unwilling or unable to tolerate the procedures and/or comply with the task instructions.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT00142493
Start Date
September 1 2004
End Date
August 1 2008
Last Update
December 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021